The combination group showed significantly greater tumor reduction compared with the IL-15 treatment group at 2, 5, 7, 10, and 12 days after NIR-PIT (p < 0.05, Tukey–Kramer test) (Figure 3C), and showed significantly greater tumor reduction compared with CD44-targeted NIR-PIT group at 5, 7, 10, and 12 days after NIR-PIT (p < 0.05, Tukey–Kramer test) (Figure 3C). The gene discussed is CD44; the disease is neoplasm.